

REMARKS

The specification is further corrected and a Sequence Listing is herein submitted to comply with the requirements of an application containing a nucleotide and/or amino acid sequence 37 C.F.R. §§ 1.821 - 1.825. The specification has been amended in the Brief Description of the Drawings (pages 24 and 25) to add sequence identifiers for the sequences set forth in Figures 14, 16 and 18.

The paper copy and computer readable copy (CD-R) of the Sequence Listing are the same. The Sequence Listing does not include new matter.


CONCLUSION

Entry of the Sequence Listing and corrections to the specification, and favorable consideration are respectfully requested.

To the extent necessary, please grant any extension of time deemed necessary for entry of this communication. Please charge any deficient fees, or credit any overpayment of fees, to Deposit Account 500417.

Respectfully submitted,
McDERMOTT, WILL & EMERY LLP

Date: October 7, 2004

By: 
Kelli N. Watson
Registration No. 47,170

600 Thirteenth Street, N.W.
Washington, D.C. 20005-3096
(202) 756-8351 (Direct)
(202) 756-8087 (Facsimile)
WDC99 985073-1.061352.0045